Literature DB >> 30199486

Role of Radiological Imaging in the Diagnosis and Characterization of Pancreatic Cystic Lesions: A Systematic Review.

Eyas Mohamed1, Richard Jackson2, Christopher M Halloran, Paula Ghaneh.   

Abstract

The evidence on the ability of radiological tests to predict a specific diagnosis and also their aptitude in identifying pathological markers indicative of malignancy in cystic lesions of the pancreas remains inconclusive. We conducted a systematic review on MEDLINE for the use of computed tomography (CT), magnetic resonance imaging, and positron emission tomography/CT (PET/CT) in the diagnosis and characterization of these cysts. The accuracy of CT scan for reaching a specific diagnosis was 39% to 61.4%, whereas its accuracy for differentiating benign from malignant lesions was 61.9% to 80%. Magnetic resonance imaging showed a better accuracy in identifying a specific diagnosis of 50% to 86%, whereas its accuracy in differentiating benign from malignant lesions was 55.6% to 87%. The use of magnetic resonance imaging was superior to CT scan in identifying septations, mural nodules, and ductal communication. The sensitivity of PET/CT in diagnosing malignancy was 85.7% to 100% with a reported accuracy of 88% to 95%. The evidence gathered from this review suggests that the adequacy of CT imaging in full characterization of pancreatic cysts is suboptimal, and therefore a low threshold for supplementary imaging is advised. The use of PET/CT should be considered in high-risk patients with equivocal findings.

Entities:  

Mesh:

Year:  2018        PMID: 30199486     DOI: 10.1097/MPA.0000000000001134

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  1 in total

1.  Multiparameter Analysis Using 18F-FDG PET/CT in the Differential Diagnosis of Pancreatic Cystic Neoplasms.

Authors:  Guanyun Wang; Haodan Dang; Peng Yu; Honghong Liu; Yue Wu; Shulin Yao; Jiahe Tian; Huiyi Ye; Baixuan Xu
Journal:  Contrast Media Mol Imaging       Date:  2021-04-07       Impact factor: 3.161

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.